Clinical effectiveness of cefiderocol for the treatment of bloodstream infections due to carbapenem-resistant Acinetobacter baumannii during the COVID-19 era: a single center, observational study.
Alessandra OlivaL LiguoriS CovinoF PetrucciF Cogliati-DezzaA CurtoloG SavelloniM ComiF SaccoG CeccarelliA ViscidoF AlessandriG RaponiF PuglieseC M MastroianniM VendittiPublished in: European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology (2024)
CFDC could represent an effective and safe treatment option for CRAB BSI, especially in patients with bacteremic HAP/VAP and frail patients where the risk of acute renal failure during therapy should be avoided.
Keyphrases
- acinetobacter baumannii
- multidrug resistant
- end stage renal disease
- coronavirus disease
- randomized controlled trial
- sars cov
- ejection fraction
- pseudomonas aeruginosa
- newly diagnosed
- systematic review
- liver failure
- stem cells
- peritoneal dialysis
- intensive care unit
- combination therapy
- mesenchymal stem cells
- extracorporeal membrane oxygenation